Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc (GSK) covers the month of February 2021. The report details the vesting of awards under the 2017 Performance Share Plan (PSP) granted in 2018 to Persons Discharging Managerial Responsibilities (PDMRs) and their Persons Closely Associated (PCAs). The performance period for these awards ran from January 1, 2018, to December 31, 2020, with vesting occurring on February 11, 2021.
Key Financial Metrics and Performance Outcomes
The filing discloses specific performance metrics used to determine vesting levels for the 2018 PSP awards. The total award vesting was 66.666%, with 33.334% lapsed.
| Performance Measure | Target/Threshold | Actual Outcome | Vesting Result |
|---|---|---|---|
| Adjusted Free Cash Flow | £12.60bn (Max) | £15.64bn | 100% of portion (33.333% of total award) |
| Total Shareholder Return (TSR) | Ranking vs. 10 peers | Ranked 9th | 0% of portion (0% of total award) |
| R&D New Products Sales | £4.387bn (Max) / £3.589bn (Threshold) | £7.337bn | 100% of portion (33.333% of total award) |
Share prices on the vesting date (February 11, 2021) were £12.552 for Ordinary Shares and $35.52 for American Depositary Shares (ADSs).
Material Changes and Transaction Details
The filing reports the vesting of equity awards for 17 individuals, including the CEO, Chief Scientific Officer, and various Senior Vice Presidents. The transactions involved the issuance of Ordinary Shares and ADSs at a price of £0.00 or $0.00, representing the vesting of previously granted conditional awards.
- CEO (Ms E Walmsley): 340,753 Ordinary Shares vested.
- CSO (Dr H Barron): 180,833 ADSs vested.
- President, Global Vaccines (Mr R Connor): 135,107 Ordinary Shares vested.
- President, Global Pharmaceuticals (Mr L Miels): 175,482 Ordinary Shares vested.
Vested shares for Executive Directors are subject to an additional two-year vesting period.
Guidance, Outlook, and Risks
This filing does not contain forward-looking guidance, management commentary on future financial outlook, or new risk factors. It is a regulatory notification of past performance outcomes and equity transactions. The filing notes that adjustments to the original target and vesting schedule were previously communicated in the 2019 Annual Report.
Key Facts for Investor Verification
- Performance Success: GSK exceeded targets for Adjusted Free Cash Flow and R&D New Product sales, achieving maximum vesting for these metrics.
- Performance Failure: GSK failed to meet the Total Shareholder Return threshold, ranking 9th out of 10 comparator companies, resulting in zero vesting for that portion of the award.
- Executive Compensation: Significant equity awards vested for senior leadership on February 11, 2021, based on the 2018-2020 performance period.
- Holdback Period: Vested shares for Executive Directors are not immediately liquid; they are subject to a further two-year vesting period.